Olympus Europa SE & Co. KG (Olympus) has announced the commercial launch of the first three applications within its OLYSENSE CAD/AI portfolio. Initially available in selected European countries, the cloud-based, integrated, and adaptable suite of seamlessly connected apps and solutions is designed to address clinical and operational performance.
Olympus says this launch marks the first step towards creating its intelligent endoscopy ecosystem. The OLYSENSE CAD/AI portfolio allows healthcare professionals to harness the power of artificial intelligence (AI), with the aim of detecting and characterising suspected tissues and lesions.
Healthcare is evolving. Gastroenterologists today face increasing challenges, like heightened workloads, administrative burdens, budget constraints, and staff shortages. At the same time, the need for endoscopic procedures is increasing in light of demographic trends and ubiquitous lower and upper gastrointestinal conditions.
Efficient screening, early diagnosis, and appropriate treatment are vital for patient outcomes. Data-driven and AI-based solutions are designed to address these demands. That is why Olympus is introducing OLYSENSE to seamlessly integrate these advanced digital technologies with endoscopic devices.
“Since developing the world’s first gastro-camera over 70 years ago, Olympus has been committed to addressing the evolving needs of both healthcare providers and patients in the field of endoscopy,” said Miquel-Àngel García, Sr. Vice Pres. and General Manager of Endoscopy Solutions Ecosystem at Olympus. “Launching an intelligent endoscopy ecosystem that connects software, hardware, and services across the whole endoscopy care pathway, is the next step on this journey.”
At launch, the OLYSENSE CAD/AI software application portfolio will include three separate cloud-based, AI-supported apps designed to assist healthcare professionals in the early diagnosis of lower and upper GI diseases during endoscopy procedures: CADDIE, CADU, and SMARTIBD. These three advanced medical device software products received the CE approval for Europe under the Medical Device Regulations (MDR) last year and are now commercially available in the region.
CADDIE, a cloud-based AI for colonoscopy, assists gastroenterologists in the detection and characterisation of suspected polyps and potential early signs of colorectal cancer. Trained on a robust dataset to identify potential colorectal lesions in colonoscopy video frames, it delivers instant image analysis on the endoscopy monitor–supporting endoscopists in making informed decisions in real time. With CADDIE, Olympus aims to positively impact the prevention and early detection of colorectal cancer by showing a 7.4% absolute increase in adenoma detection rate (ADR) compared to standard of care.
A multi-centre randomised controlled trial conducted across eight European hospitals demonstrated the technology’s potential for hard-to-detect and high-risk polyps: When CADDIE was utilised in said trial, endoscopists achieved a relative increase of 136% in detected large polyps and 93% in detected large adenomas. Additionally, they detected 2.3 times more sessile serrated lesions (SSL), the most common precancerous serrated polyps, and up to 57% more flat adenomas, relative to when they did not use the AI system during a procedure.
“Cloud-based and AI-powered endoscopy solutions are transforming clinical practice. By enabling real-time decision support and standardized assessments, they help clinicians diagnose earlier and more accurately, streamline workflows, and improve patient outcomes”, comments Prof. Cesare Hassan, Gastroenterologist from the Humanitas University in Milan, Italy. “Endoscopy on the cloud opens the door for continuous innovation and broader access to advanced care.”
While CADDIE contributes to the detection and characterisation of colorectal polyps, the second AI-powered application CADU addresses another gastrointestinal condition known as Barrett’s Esophagus. It highlights areas with the highest likelihood of dysplasia in endoscopy images, aiming to support healthcare professionals in accurate clinical decision-making.
Finally, the third algorithm SMARTIBD assists in the analysis of Ulcerative Colitis in line with the MAYO scoring. The three applications underpin OLYSENSE CAD/AI’s diverse capabilities within the endoscopy unit to contribute to improving patient outcomes across various disease states.
In the future, the ecosystem’s applications and offerings will continue to evolve, complementing its AI-powered clinical solutions with seamless data connectivity across the GI unit and integration with hospital systems to drive clinical and operational efficiency as well as simplicity.
“The commercial launch of our OLYSENSE CAD/AI applications marks an exciting milestone, as we introduce the first component of our intelligent endoscopy ecosystem and provide our customers with an innovative, cloud-based solution that can help them advance their clinical performance,” said Oliver Burghardt, Vice Pres. Medical Endoscopy Group for Olympus EMEA.
Related
The post Olympus launches first applications in OLYSENSE AI portfolio first appeared on TechToday.
This post originally appeared on TechToday.